NEUREN’S VALUE PROPOSITION arge potential upside for shareholders is enabled by financial strength 1 Maximise value of NNZ-2591 as a multiple indication platform Positive Phase 2 results for Phelan-McDermid syndrome Positive Phase 2 results for Pitt Hopkins syndrome Positive Phase 2 results for Angelman syndrome Long-term income growth from Acadia’s successful global commercialization of Value A$359 million pro-forma cash1 222 million cash and short-term investments at 31 December 2024, adjusted to include receipt in Q1 2025 of PRV sale proceeds, sales milestone and Q4 2024 royalty and payment in Q1 2025 of Q4 2024 tax Comprehensive income (CI) A$166m The 2024 numbers – a record year of income for shareholders 2 0.2 157.1 166.2 2022 2023 2024 Total comprehensive income (A$m) CI margin 73% NPAT A$142m FX gain A$24m Corporate & admin costs A$5m R&D investment in NNZ-2591 A$33m DAYBUE revenue 23 & 24 A$445m Pro-forma cash A$359m Comprehensive income (CI) A$166m CI margin 73% NPAT A$142m FX gain A$24m Corporate & admin costs A$5m R&D investment in NNZ-2591 A$33m DAYBUETM revenue 23 & 24 A$445m Pro-forma cash1 A$359m THE 2024 NUMBERS – A RECORD YEAR OF INCOME FOR SHAREHOLDERS 1 A$222 million cash and short-term investments at 31 December 2024, adjusted to include receipt in Q1 2025 of PRV sale proceeds, sales milestone and Q4 2024 royalty and payment in Q1 2025 of Q4 2024 tax. This is a non-IFRS measure and is relevant to illustrate the expected cash and short-term investments position, due to the large proportion of 2024 revenue being earned in Q4 2024 and received in Q1 2025. Neuren Pharmaceuticals Limited Annual Report 2024 1
RkJQdWJsaXNoZXIy MjE2NDg3